Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovaBridge Biosciences (NBP) Equity Income (2020 - 2024)

NovaBridge Biosciences (NBP) has 3 years of Equity Income data on record, last reported at $2.1 million in Q4 2024.

  • On a quarterly basis, Equity Income rose 371.73% to $2.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.0 million, a 79.14% decrease, with the full-year FY2025 number at $5.2 million, up 397.5% from a year prior.
  • Equity Income reached $2.1 million in Q4 2024 per NBP's latest filing, up from -$1.0 million in the prior quarter.
  • Over the last five years, Equity Income for NBP hit a ceiling of $10.2 million in Q4 2020 and a floor of -$2.4 million in Q3 2023.
  • A 3-year average of $1.0 million and a median of -$901000.0 in 2023 define the central range for Equity Income.
  • On a YoY basis, Equity Income climbed as much as 371.73% in 2024 and fell as far as 371.73% in 2024.
  • Tracing NBP's Equity Income over 3 years: stood at $10.2 million in 2020, then plummeted by 107.51% to -$764000.0 in 2023, then skyrocketed by 371.73% to $2.1 million in 2024.
  • Business Quant data shows Equity Income for NBP at $2.1 million in Q4 2024, -$1.0 million in Q1 2024, and -$764000.0 in Q4 2023.